Drug Profile
Ciprofloxacin inhalation - Bayer/Novartis
Alternative Names: Bay q 3939; BAYQ3939; Cipro DPI; Cipro inhale; Ciprofloxacin PulmoSphere®; Ciprofloxin inhalation powder programmeLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bayer HealthCare; Nektar Therapeutics
- Developer Bayer HealthCare; Novartis
- Class Anti-infectives; Antibacterials; Carboxylic acids; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
- Mechanism of Action DNA gyrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cystic fibrosis-associated respiratory tract infections; Pneumonia; Pseudomonal infections; Respiratory tract infections
- Discontinued Bronchiectasis
Most Recent Events
- 18 May 2018 Efficacy data from the phase III RESPIRE 1 and RESPIRE 2 trial in Bronchiectasis (Non-cystic fibrosis related) presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
- 03 Apr 2018 No recent reports of development identified - Phase-III for Pneumonia in Japan (Inhalation)
- 01 Oct 2016 Bayer and Novartis completes the phase III RESPIRE-2 trial in Bronchiectasis (Non-cystic fibrosis related) in USA, Argentina, Brazil, Australia, Austria, Bulgaria, Czech Republic, Germany, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Slovakia, South Africa, South Korea, Hong Kong, China, Philippines, Taiwan, Thailand, Turkey, Serbia and Russia (NCT02106832)